PI-88 in Hepatocellular Carcinoma After Hepatectomy

Inclusion Criteria:

* Patients have voluntarily given written informed consent
* Age ≥ 18 years but ≤ 75 years
* Males or females
* Histological diagnosis of hepatocellular carcinoma
* Curative hepatectomy within the past 4-6 weeks
* ECOG performance status of 0 to 2
* Cardiac functional capacity ≤ to class II (New York Heart Association)
* Patients with adequate renal, hepatic, and haematopoietic function as defined by:

  * Serum creatinine ≤ 2.0 mg/dL
  * Total bilirubin \< 2.5 mg/dL
  * Neutrophil count \> 1.5 x 10\^9/L
  * ALT \< 5 x upper limit of normal (ULN)
  * White blood cell (WBC) count ≥ 3 x 10\^9/L
  * Platelet count ≥ 80 x 10\^9/L
  * Prothrombin time international normalized ratio (PT-INR) ≤ 1.3 (or PT-INR ≤ 1.4 but PT within normal range)
  * Activated partial thromboplastin time (APTT) \< ULN

Exclusion Criteria:

* Patients with history of allergy and/or hypersensitivity to anticoagulants/thrombolytic agents, especially heparin.
* Patients with history of immune mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or other platelet disease
* Patients with previous positive result in a heparin-induced thrombocytopenia (HIT) antibody test.
* Patients with any tumour metastasis.
* Patients with uncontrolled infection or serious infection within the past 4 weeks.
* Patients with myocardial infarction, stroke, or congestive heart failure within the past 3 months.
* Patients with history of inflammatory bowel disease, any other abnormal bleeding tendency, or patients at risk of bleeding due to open wounds or planned surgery.
* Patients with acute or chronic gastrointestinal bleeding within the past 1 year.
* Patients with a history of drug abuse or psychiatric disorder.
* Patients with known HIV infection or AIDS-related illness.
* Patients who received other investigational or anti-neoplastic medication within the past 4 weeks.
* Use of aspirin, aspirin-containing medications, non-steroidal anti-inflammatory drugs (except for COX-2 inhibitors), heparin, low molecular weight heparin, warfarin, anti-platelet drugs, or any other anticoagulant medications 2 weeks prior to or during the study period.
* Women who are pregnant or breast-feeding.
* Women of child-bearing potential who are not using an adequate method of contraception.